Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06514196

Post- Approval Hintermann Series H® Study 1

The H3 TAR device received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) on June 4, 2019, and as a condition of that approval, this study is being conducted to provide long-term safety and effectiveness of the H3 TAR System among patients included in the Primary Safety and Effectiveness (PSE) Cohort (P1600361).

This will be a Prospective, single-center, single arm study.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Ankle Osteoarthritis Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder) Post-Traumatic Osteoarthritis of Ankle

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kantonsspital Baselland

Bruderholz, CH-4101, Switzerland

About this study

The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.).

This will be a Prospective, single-center, single arm study. All living subjects who participated in the PSE cohort, regardless of whether or not the subject has had a revision/removal followed through the 10-year post-operation visit. 298 subjects were originally included in the PSE cohort.

Through 10 years follow up. Based on the last surgery date, it is projected the study will be completed with the final 10-year follow-up visit to occur in December 2024.

Patients will undergo clinical and radiographic evaluation at 5 and 10 years (+/- 90 days) post-operation.

Performance Goals (PGs) will be constructed for the 10-year endpoint. As with the PGs used in the PMA study, these will be based on a prospectively defined, systematic meta-analysis of available published literature and registry data for the control (a legally marketed mobile bearing ankle). The details of the meta-analysis will be pre-specified in a protocol for this purpose. Both the protocol and the meta-analysis will be completed prior to the completion of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Skeletally mature
  • Primary diagnosis of osteoarthritis, post-traumatic arthritis or rheumatoid arthritis
  • Primary total ankle replacement
  • Unilateral or the first ankle implanted if bilateral and the surgery dates for both sides are at least 6 months apart
  • Implanted with the correct device without screws (for investigational arm),
  • 3rd generation Hintermann Series H3 Total Ankle Replacement;
  • Poor pre-operative American Orthopaedic Foot and Ankle Society Hindfoot Score (< 60 points)
  • Implanted in 2013 or earlier). Note that all subjects implanted in 2013 or earlier were included regardless of whether they were revised prior to the 2 year endpoint.
  • Gave informed consent (unless IRB/Ethics Committee waived this requirement)

Exclusion criteria

  • Prior TAR or arthrodesis at the involved ankle joint

Treatment and study plan

Hintermann Series H3 Total Ankle Replacement System

Device

The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.

Primary outcomes

  1. AOFAS Score Measurement

    Time frame: 10 Years

    The American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score is among will be used for measuring the outcome of treatment in patients who sustained a complex ankle or hindfoot injury. It will be measured at a minimum 10 years post-operation

  2. Survivorship Measurement

    Time frame: 10 Years

    Survivorship (absence of removal/revisions to include polyethylene revision) will be recorded at 10 years from surgery

  3. Serious device-related adverse event Measurement

    Time frame: 10 Years

    Percentage of subjects with a serious device-related adverse event, other than a revision or removal will be calculated at 10 years from surgery

  4. Reoperation, revisions or removals Measurement

    Time frame: 10 Years

    Safety Reporting of the reoperation, revisions or removals of the Hintermann Ankle device will be reviewed and analyzed

  5. Serious Device-Related Adverse Events Measurement

    Time frame: 10 Years

    Incidence, occurrence, and types of serious device-related adverse events will be reviewed and analyzed for subjects Nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome of any adverse event will be measured.

  6. Device Explant Analysis Measurement

    Time frame: Through Study Completion an Average of 10 years

    Any explanted devices / device components will be returned and handled for analysis as described in Attachment G: Explant and Revision Protocol, to be examined for wear and damage.

Sponsors and collaborators

Lead sponsor

DT MedTech, LLC

Industry

Registry information

Official study title

Post- Approval Study 1: Long Term Follow Up of the Hintermann Series H® Total Ankle Replacement System

Important dates

Study start
2020
Primary completion
2024
Study completion
2025
First posted
Jul 23, 2024
Registry last updated
Jul 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.